Myasthenia Gravis

 Myasthenia gravis is an autoimmune disorder affecting the myoneural junction which is a synapse formed between motor neuron  and a muscle fiber. MG   is characterized by varying degrees of weakness of the voluntary muscles.

In MG, the receptors at the muscle surface are destroyed or deformed by antibodies that prevent a normal muscular reaction from occurring.

The causative factor is unknown, but the disorder may have a genetic link. The  risk factors may include  presence of other autoimmune disorders,  presence of thymoma which is a rare, usually benign tumor arising from thymus tissue. MG occurs at any age and in any race. The incidence is approximately

 9 to 21 cases per million persons. MG is most common in women, incidence in females peaks at ages 30 to 39 and in males at ages 60 or older.

Please watch the video provided in the hyperlink about some key points to understand Myasthenia gravis.

Factors that can worsen myasthenia gravis symptoms are Fatigue

Illness/infection

Stress/emotional distress

Extreme heat

Some medications — such as beta blockers, calcium channel blockers, quinine and some antibiotics such as Fluoroquinolones and  aminoglycosides can make MG symptoms worse.

The clinical manifestations of Myasthenia gravis include  Diplopia (double vision) and Ptosis which is drooping of the eye lid. Weakness of the muscles of the face and the throat, and generalized weakness. Patient experience extreme muscle weakness and fatigue especially at the end of the day. Weakness of the facial muscles results in bland facial expression. Laryngeal irritation causes voice impairment and dysphonias and increases the patient’s risk for choking and aspiration. Generalized weakness of all the extremities and the intercoastal muscles results  in decreased respiratory capacity. Myasthenia gravis is purely a motor disorder with no effect on the sensation and coordination.

The complications of MG involve

Respiratory Distress

Acute Respiratory failure

Atelectasis

Pneumonia

Dysphagia

Aspiration

Myasthenic Crisis which is  exacerbation of MG requiring mechanical ventilation related to weakness of the respiratory muscles.

Cholinergic Crisis causing neuromuscular weakness and respiratory failure related to use of high-dose cholinesterase inhibitors

The diagnostic studies for MG involve complete  history and physical.

Edrophonium  also called Tensilon Test is used for diagnostic purposes.

 IV Injection of the chemical edrophonium (Tensilon) may result in a sudden, although temporary, improvement in muscle strength - an indication that patient may have myasthenia gravis.

Tensilon is an anticholinesterase agent and it temporarily shows improved muscle contractility . It  Inhibits destruction of  acetylcholine by cholinesterase and facilitates transmission of impulses across myoneural junction. Tensilon does not improve muscle weakness but it can make it worse, therefore  Atropine which is an  antidote to Tensilon  should be readily available to counteract its  effects.


Presence of abnormal antibodies that disrupt the receptor sites where nerve impulses signal muscles to move can help in diagnosis of MG.

Cooling may improve neuromuscular transmission. Ice pack test result for the patients whom Tensilon test is contraindicated reveal  decreased ptosis after application of ice for 60 seconds to the closed eyelid.

CT scan for thymus will show presence of thymoma.

The treatment of MG includes use of  Anticholinesterase  agents such as pyridostigmine and neostigmine. Pyridostigmine ( Mestinon) is the most successful drug for long term treatment of MG. Cholinesterase inhibitors  enhance function of neuromuscular junction by inhibiting acetylcholinesterase enzyme which breaks down acetylcholine .It helps in prolonging the action of Acetylcholine and facilitate transmission of impulses.

Corticosteroids such as Prednisone and Immunosuppressants such as Imuran, Cyclosporine (Sandimmune), mycophenolate (cellcept) are used in treatment of MG.

Plasmapheresis  is also an  option for treatment of MG for the   exchange of  plasma  to remove antibodies.

IVIG treatment  requires close monitoring for any possible reactions.

Patients may require surgical intervention  called thymectomy  to remove the thymus gland to control symptoms of MG.

The nursing assessment for MG involves assessment for the severity of the symptoms, respiratory effort including rate and  depth of respirations, oxygen saturation, ABGs and PFT . Assessing muscle strength of face  and limbs and assessment of swallowing, speech , cough and gag reflexes. Assess patient’s coping abilities so that appropriate resources can be provided.

The main goal of treatment for MG patients is the return of normal muscle endurance,  being able to manage fatigue, avoid complications and

maintain a quality of life appropriate to the disease process.

One of the priority intervention of nursing management for MG is maintaining adequate ventilation. Ensure patent airway and monitor for myasthenic crisis for increased respiratory distress and failure. Make sure that emergency respiratory equipment is readily available at the bed side. If assisting with diagnostic testing, monitor for adverse effects of Tensilon testing. Monitor for side effects of drug therapy. Know the difference and onset of manifestations of myasthenic crisis and cholinergic crisis.

Myasthenic crisis is the  exacerbation of MG symptoms following precipitating factors or failure to take medications. The patients will have improved strength  after IV administration  of anticholinergic drugs.

However, Cholinergic  Crisis  occurs after overdose of anticholinesterase  drugs resulting in excess accumulation of  Acetylcholine at receptor sites of neuromuscular junction. The muscles stop responding to overdose of Acetylcholine and results in increased  weakness within 1 hour of taking the dose. The patients will require to be withdrawn from anticholinesterase medication, mechanical ventilation if respiratory symptoms are severe and administration of Atropine.

Educate patient on balanced diet with nutrient dense foods. Encourage patient to chew slowly and note any changes in the ability to chew. Encourage the use of thickened liquids,  semi solid diet that is easy to be chewed and swallowed  if patient has difficulty swallowing.

Appropriate scheduling of medications is critical  so that the peak time for the medication is at the at mealtime. Pyridostigmine(Mestinon)should be scheduled  45 to 60 minutes before meal time and should be given with a small amount of food to prevent GI upset, but the patient should wait  45 to 60 minutes to eat a full meal  due to the potential for aspiration. If difficulty with swallowing occurs, then patient should seek immediate attention. Mestinon dose can change on a day-to-day basis depending on  manifestations of the disease.

Encourage patient to do physical demanding activities early in the day as muscles are generally strongest in the morning. Educate patient on the importance of compliance with medication regimen.

The patient should be made aware of the complications of therapy such as cholinergic crisis. Provide community resources such as Myasthenia  Gravis Associations and  MG support groups.